Gut microbiota diversity and specific composition during immunotherapy in responders with non-small cell lung cancer

Cancer immunotherapy including immune checkpoint inhibitors (ICI) has revolutionized non-small cell lung cancer (NSCLC) therapy. Recently, the microbiota status “before” initiation of ICI therapy has been emphasized as a predictive biomarker in patients undergoing ICI therapy. However, the microbiot...

Descripción completa

Detalles Bibliográficos
Autores principales: Shoji, Fumihiro, Yamaguchi, Masafumi, Okamoto, Masaki, Takamori, Shinkichi, Yamazaki, Koji, Okamoto, Tatsuro, Maehara, Yoshihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Molecular Biosciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638091/
https://www.ncbi.nlm.nih.gov/pubmed/36353732
http://dx.doi.org/10.3389/fmolb.2022.1040424

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638091/
https://www.ncbi.nlm.nih.gov/pubmed/36353732
http://dx.doi.org/10.3389/fmolb.2022.1040424

Ejemplares similares